Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to
evaluate the efficacy of activated recombinant human factor VII to mitigate
experimentally-induced bleeding in healthy volunteers treated with warfarin to reach a
targeted INR (International Normalization Ratio).